Stem cell-based therapies in neonatology: a new hope

Thébaud, Bernard

doi:10.1136/archdischild-2017-314451

Cited by 11 publications

(6 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent Canadian workshop group of neonatologists acknowledged cell-based therapies as promising for BPD (22), and highlighted that successful translation requires careful consideration of antenatal, perinatal, and postnatal factors. They and others also emphasize the need for evidence-based approaches in designing and executing these studies (23, 24). Our study provides epidemiologic evidence that HPSCs and MSCs present at birth vary in concentration among preterm infants who later develop BPD.…”

Section: Discussionmentioning

confidence: 99%

Variations in Umbilical Cord Hematopoietic and Mesenchymal Stem Cells With Bronchopulmonary Dysplasia

et al. 2019

View full text Add to dashboard Cite

Objective: To test the hypothesis that umbilical cord blood-derived CD34+ hematopoietic stem cells (HPSC), cord tissue-derived CD90+ and CD105+ mesenchymal stem cells (MSC) vary with bronchopulmonary dysplasia (BPD).Methods: We conducted a prospective longitudinal study at a large birth center (Prentice Women's Hospital in Chicago, IL). Premature infants (N = 200) were enrolled in 2:1:1 ratio based on gestational age (GA): mildly preterm (31–32 weeks), moderately preterm (29–30 weeks), and extremely preterm (23–28 weeks). Cord blood (CB) and cord tissues (CT) were collected at birth using commercial banking kits, and analyzed for collection blood volume, tissue mass, CD34+, CD90+, CD105+ counts, and concentrations. Multiplex immunoassay was used to measure 12 cytokines and growth factors in CB plasma of 74 patients. BPD severity was defined according to NIH consensus definitions. Univariate and multivariate regression models were used to identify perinatal covariates and assess associations between stem cell concentrations, cytokines, and BPD outcomes.Results: Of 200 patients enrolled (mean GA = 30 ± 2 weeks), 30 developed mild, 24 moderate, and 19 severe BPD. Concentrations of HPSC and MSC, as measured by %CD34+, %CD90+, and %CD105+ of total cells, increased with degree of prematurity. Collection parameters varied with GA, birth weight (BW), gender, prolonged rupture of membranes, mode of delivery, chorioamnionitis, and multiple gestation. Moderate-severe BPD or death was increased with lower GA, BW, Apgar scores, and documented delayed cord clamping. %CD34+ and %CD90+ were increased with BPD and directly correlated with BPD severity. Severe BPD was positively associated with %CD34+ (beta-coefficient = 0.9; 95% CI = 0.4–1.5; P < 0.01) and %CD90+ (beta-coefficient = 0.4; 95% CI = 0.2–0.6; P < 0.001) after adjustment for covariates. CB plasma granulocyte-colony stimulating factor (G-CSF) was inversely associated with %CD90+, and decreased with BPD. Below median G-CSF combined with elevated %CD90+ predicted BPD (positive predictive value = 100%).Conclusions: CB and CT collections yielded high concentrations of HPSCs and MSCs in BPD infants, accompanied by low circulating G-CSF. These variations suggest possible mechanisms by which stem cell differentiation and function predict BPD.

show abstract

Section: Discussionmentioning

confidence: 99%

Variations in Umbilical Cord Hematopoietic and Mesenchymal Stem Cells With Bronchopulmonary Dysplasia

et al. 2019

View full text Add to dashboard Cite

show abstract

“…This process is mimicking the behavior of circulating progenitor cells during cancer development (109). Nowadays cell-based therapies are becoming more relevant (119,120) and considering the homing properties of endothelial precursor cells (109,121), it could be possible to engineer such early EPCs that would carry therapeutic genes and targeting angiogenesis (109,122,123). Collet et al confirmed this hypothesis (118).…”

Section: Vascular Normalization Strategies Vs Anti-angiogenic Therapiesmentioning

confidence: 94%

Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies

et al. 2021

View full text Add to dashboard Cite

The environmental and metabolic pressures in the tumor microenvironment (TME) play a key role in molding tumor development by impacting the stromal and immune cell fractions, TME composition and activation. Hypoxia triggers a cascade of events that promote tumor growth, enhance resistance to the anti-tumor immune response and instigate tumor angiogenesis. During growth, the developing angiogenesis is pathological and gives rise to a haphazardly shaped and leaky tumor vasculature with abnormal properties. Accordingly, aberrantly vascularized TME induces immunosuppression and maintains a continuous hypoxic state. Normalizing the tumor vasculature to restore its vascular integrity, should hence enhance tumor perfusion, relieving hypoxia, and reshaping anti-tumor immunity. Emerging vascular normalization strategies have a great potential in achieving a stable normalization, resulting in mature and functional blood vessels that alleviate tumor hypoxia. Biomarkers enabling the detection and monitoring of tumor hypoxia could be highly advantageous in aiding the translation of novel normalization strategies to clinical application, alone, or in combination with other treatment modalities, such as immunotherapy.

show abstract

“…Descubiertas en 1976, las MSC se describieron por primera vez en la médula ósea como células similares a fibroblastos cruciales para la regulación de las células madre hematopoyéticas. (Thébaud, 2018) Las células madre tienen la capacidad de dar origen a cualquier otra célula del cuerpo y reemplazar a las que se van muriendo, o liberar al entorno moléculas que contribuyen en la reparación de daños provocados por enfermedades, traumas y el mismo fenómeno de envejecimiento. Estas células madre poseen al menos dos características principales: tienen la capacidad de diferenciarse en cualquier tipo de célula especializada, si reciben el estímulo adecuado (diferenciación), al tiempo que pueden conservarse como tales y producir indefinidamente células madre (autorenovación).…”

Section: Introductionunclassified

Tratamiento con células madres en neonatos

Neira¹,

Barreto²,

Ortega³

et al. 2023

RECIMUNDO

View full text Add to dashboard Cite

A pesar de los avances en el cuidado del bebé prematuro, varias complicaciones graves que conducen a secuelas significativas siguen siendo un desafío clínico. Displasia broncopulmonar (DBP), complicaciones gastrointestinales y lesión neurológica aún afectan a un gran número de lactantes, lo que lleva no sólo a mortalidad y morbilidad en cuidados intensivos neonatales (UCIN), sino también a la reducción a largo plazo en la calidad de vida. La terapia con células madres ha surgido como un potencial enfoque prometedor terapéutico en el manejo de las complicaciones comunes de prematuridad. La metodología utilizada para el presente trabajo de investigación, se enmarca dentro de una revisión bibliográfica de tipo documental. La técnica para la recolección de datos está constituida por materiales electrónicos, estos últimos como Google Académico, PubMed, entre otros, apoyándose para ello en el uso de descriptores en ciencias de la salud o terminología MESH. La información aquí obtenida será revisada para su posterior análisis. Las terapias con células madres son el futuro de la medicina, sin embargo, su manejo es delicado, y por ello debe haber protocolos estandarizados para su aislamiento, manipulación, expansión in vitro y administración. Hay diferentes tipos de células madres que se extraen de la medula ósea, cordón umbilical, tejido adiposo, piel, entre otros. Las terapias para su utilización en neonatos siguen controvertidas por la falta de evidencias solidas que avalen su uso, para la certificación de su eficacia. La gran ventaja de las terapias de células madres es su poder de regeneración, por su capacidad de dar origen a otras células, y que puedan recuperar anatómica y funcionalmente tejidos, órganos y sistemas, que en la actualidad conducen a enfermedades crónicas, como las que se puede presentar en neonatos.

show abstract

Stem cell-based therapies in neonatology: a new hope

Cited by 11 publications

References 46 publications

Variations in Umbilical Cord Hematopoietic and Mesenchymal Stem Cells With Bronchopulmonary Dysplasia

Variations in Umbilical Cord Hematopoietic and Mesenchymal Stem Cells With Bronchopulmonary Dysplasia

Tumor Hypoxia Regulates Immune Escape/Invasion: Influence on Angiogenesis and Potential Impact of Hypoxic Biomarkers on Cancer Therapies

Tratamiento con células madres en neonatos

Contact Info

Product

Resources

About